Sacituzumab Tirumotecan (Sac-TMT/SKB264) Plus Tagitanlimab (KL-A167) in Patients With Recurrent or Metastatic Esophageal Squamous Cell Carcinoma and Gastric/Gastroesophageal Junction Adenocarcinoma
Conditions : ESCC; Gastric Adenocarcinoma; Gastroesophageal Junction Adenocarcinoma; Esophageal Squamous Cell Carcinoma (ESCC); GC/GEJC Interventions : Drug: Sacituzumab Tirumotecan + Tagitanlimab…
Read the full article3d agoen
You might also wanna read
Preadmission GLP-1 Receptor Agonist Plus SGLT2 Inhibitor Use and Early Outcomes After Pneumonia Hospitalization in Adults With Type 2 Diabetes
clinicaltrials.gov·just now
Comprehensive study finds no link between mobile phones and brain cancer
theconversation.com·1h ago
New CRISPR Tool Enables Control of Ribosomal RNA to Target Protein-Related Diseases
scitechdaily.com·1h ago
NHS study finds focal therapy for prostate cancer as effective as surgery with fewer side effects
bbc.co.uk·3h agoNorwegian Study of 740,000 Children Finds No Link Between Rotavirus Vaccine and Celiac Disease
historyofvaccines.org·4h agoNorwegian Study of 740,000 Children Finds No Link Between Rotavirus Vaccine and Celiac Disease
historyofvaccines.org·4h ago
Comments
Sign in to join the conversation.
No comments yet. Be the first.